Ask AI
ProCE Banner Activity

How to Implement Earlier Hepatitis B Treatment

Podcast

Listen as Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, review strategies for more expansive HBV treatment while considering adverse events, cost-effectiveness, and patient perspectives. 

Released: March 26, 2024

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Hepatitis B Foundation

ProCE Banner

Financial Disclosures

Primary Author

Jacki Chen, PhD

Patient Advocate

Jacki Chen, PhD: consultant/advisor/speaker: GlaxoSmithKline.

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology & Hepatology
Weill Cornell Medicine
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: Gilead, GSK, Ipsen, Madrigal, Mirum, Vir; researcher: Gilead, Ipsen, Madrigal.

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Stanford, California

 

 

 

Paul Kwo, MD: consultant/advisor/speaker: Aligos, Amgen, Ausper Bio, Genentech, Gilead, GSK, HepQuant, Inventiva, Lygenesis, Mirum, Novo Nordisk, Precision, Salix, Target RWE, Tune; researcher: Akero, Altimmune, 89BIO, Madrigal, Ultragenyx, VirBio.

Mark Sulkowski, MD, FAASLD

Professor of Medicine
Director, Department of Medicine
Johns Hopkins Bayview Medical Center
Senior Associate Dean for Clinical Trials
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark Sulkowski, MD, FAASLD: researcher: Aligos, Grifols, GSK, Vir; consultant/advisor/speaker: AstraZeneca, Precision, Virion; independent contractor: Gilead, Wiley.